On September 13, 2022, Green Vision Biotechnology Corp. (the “Company”) announced that the Company’s Board of Directors has determined to effect a suspension of its reporting obligations under Section 15(d) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), by voluntarily filing a Form 15 with the Securities and Exchange Commission (“SEC”) on September 20, 2022. Upon the filing of the Form 15, the Company’s obligation to file certain Exchange Act reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, will immediately be suspended. The Company intends to maintain its public listing on the OTC Pink Sheets market and plans to continue to disclose company information via the OTC Markets reporting service.
For more information, please see the company’s form 8k, https://www.otcmarkets.com/stock/GVBT/overview, filed September 14, 2022, which also includes the company’s press release relating to this matter and its form 15, filed on September 30, 2022. https://www.otcmarkets.com/stock/GVBT/overview.
